1. Pink Sheet
  3. >>Biosimilars

New Biosimilars Council Head Seeks Insulin Lessons As More Biosimilar Launches Loom

 
• By Derrick Gingery

Craig Burton, who replaces the FDLI-bound Christine Simmon, tells the Pink Sheet that fighting rebating practices which harm insulin patients now can pave the way for successful launches of Humira biosimilars next year. Biosimilar markets should not be ‘winner-take-all,’ he says.

Lessons learned
The roll-out of insulin biosimilars could inform policy to improve the upcoming launch of Humira biosimilars, new Biosimilars Council Executive Director Craig Burton said. • Source: Shutterstock

Incoming Biosimilars Council Executive Director Craig Burton wants the industry and policymakers to learn from the launch of insulin biosimilars in time for the widely anticipated debut of competitors to AbbVie Inc.’s Humira (adalimumab).

Burton, the Association for Accessible Medicines’ VP of policy since 2017, replaceed Christine Simmon as head of AAM’s biosimilar industry advocate on 30 May

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Biosimilars & Generics